title: Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
abstract: A 5-year retrospective analysis of fungemia in patients with hematologic malignancies revealed that four patients, who received fluconazole and itraconazole during neutropenia, developed breakthrough candidemia due to azole-resistant Candida tropicalis isolates. This observation suggests that causative organisms of candidemia in neutropenic patients receiving azoles should be suspected of being azole-resistant.
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Myoken
authors.forename: Tai-ichi
authors.initials: T
authors.lastname: Kyo
authors.forename: Megumu
authors.initials: M
authors.lastname: Fujihara
authors.forename: Tatsumi
authors.initials: T
authors.lastname: Sugata
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Mikami
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use*; D041022:Candida tropicalis / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology*; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D001393:Azoles